Healthcare PharmaceuticalsRoche's anti-CD20 chimeric monoclonal antibody (rituximab) co-developed by Genentech and IDEC Pharmaceuticals, FDA approved November 26, 1997, as the first monoclonal antibody approved for cancer treatment, now facing biosimilar competition from Truxima, Ruxience, and Riabni.
oncologylymphomarituximab